2-羟基-2,2-二(噻吩-2-基)乙酸乙酯 | 28569-88-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: 2-羟基-2,2-二(噻吩-2-基)乙酸乙酯
• 英文名称: Ethyl (2,2'-Dithienyl)glycolate
• 英文别名: hydroxy-di-[2]thienyl-acetic acid ethyl ester；Hydroxy-di-[2]thienyl-essigsaeure-aethylester；hydroxy-di-thiophen-2-yl-acetic acid ethyl ester；ethyl hydroxy(dithiophen-2-yl)acetate；2-hydroxy-dithiophen-2-yl-acetic acid ethyl ester；ethyl hydroxyl (dithiophen-2-yl)acetate；Ethyl 2-hydroxy-2,2-DI(thiophen-2-YL)acetate；ethyl 2-hydroxy-2,2-dithiophen-2-ylacetate
• CAS: 28569-88-2
• 化学式: C₁₂H₁₂O₃S₂
• 分子量: 268.357
• InChiKey: UPTVHSCRWQCIOS-UHFFFAOYSA-N

物化性质

• 熔点：
  53-56 °C
• 沸点：
  146-146.5 °C(Press: 2 Torr)
• 密度：
  1.347±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-羟基-2,2-二(噻吩-2-基)乙酸乙酯 在 氢氧化钾 、 三氯化铝 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 (5-Phenyl-2-thienyl)(2-thienyl)acetic acid
  参考文献：
  名称：

  Study of some thiophene analogs of glycolic acid

  摘要：

  DOI：

  10.1021/jo00327a009
• 作为产物：
  描述：

  2-噻吩基锂 、 2-噻酚乙酯乙酸乙酯 以53%的产率得到2-羟基-2,2-二(噻吩-2-基)乙酸乙酯
  参考文献：
  名称：

  Study of some thiophene analogs of glycolic acid

  摘要：

  DOI：

  10.1021/jo00327a009

文献信息

• [EN] QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE QUINUCLIDINE ET LEUR UTILISATION COMME ANTAGONISTES DES RÉCEPTEURS MUSCARINIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2009139710A1

  公开（公告）日：2009-11-19

  The invention provides compounds of formula (I) wherein R1, R2, R3, Het1, n, Y and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation

  本发明提供了公式(I)的化合物，其中R1、R2、R3、Het1、n、Y和X如说明书中所定义，一种制备它们的方法，包含它们的药物组合物，制备药物组合物的过程，它们在治疗中的用途以及用于它们制备的中间体。
• Muscarinic receptor antagonists
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2130830A1

  公开（公告）日：2009-12-09

  The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.

  本发明一般涉及肌碱受体拮抗剂，这些拮抗剂可用于治疗通过肌碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病，除其他用途外。该发明还涉及所述化合物的制备过程、含有所述化合物的药物组合物以及治疗通过肌碱受体介导的疾病的方法。本文还提供了含有一种或多种肌碱受体拮抗剂和至少一种其他活性成分的药物组合物，包括但不限于皮质类固醇、β-激动剂、白三烯拮抗剂、5-脂氧合酶抑制剂、抗组胺药、止咳药、多巴胺受体拮抗剂、趋化因子抑制剂、p38 MAP激酶抑制剂和PDE-IV抑制剂。
• MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：KUMAR Naresh

  公开号：US20090326004A1

  公开（公告）日：2009-12-31

  The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.

  本发明涉及一般用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病的毒蕈碱受体拮抗剂。该发明还涉及所述化合物的制备过程、含有所述化合物的药物组合物以及治疗通过毒蕈碱受体介导的疾病的方法。本文还提供了包含一种或多种毒蕈碱受体拮抗剂和至少一种其他活性成分的药物组合物，包括但不限于皮质类固醇、β-激动剂、白三烯拮抗剂、5-脂氧合酶抑制剂、抗组胺药、止咳药、多巴胺受体拮抗剂、趋化因子抑制剂、p38 MAP 激酶抑制剂和 PDE-IV 抑制剂。
• Studies on spasmolytics. III. Synthesis and anticholinergic activity of 4-acyloxy-1-(1,3-dioxolan-2-ylmethyl)piperidines and their quaternary salts.
  作者：SABURO SUGAI、YOSHIHIRO HASEGAWA、YOSHIO KAJIWARA、SEIICHIRO YOSHIDA、SANYA AKABOSHI

  DOI：10.1248/cpb.32.1126

  日期：——

  Twenty-one derivatives of 4-acyloxy-1-(1, 3-dioxolan-2-ylmethyl) piperidines (2) and their quaternary salts (6) were synthesized and tested for anticholinergic activities. The piperidine derivatives (2) exhibit moderate activities. Among the quaternary salts (6), the trans-isomers were always more active than the corresponding cis-isomers.

  合成了21种4-酰氧基-1-(1,3-二氧烷-2-基甲基)哌啶衍生物（2）及其季铵盐（6），并测试了它们的抗胆碱活性。这些哌啶衍生物（2）表现出中等活性。在季铵盐（6）中，顺异构体的活性总是高于相应的反异构体。
• [EN] IMPROVED PROCESS FOR ACYL TRANSFER REACTIONS<br/>[FR] PROCÉDÉ AMÉLIORÉ POUR RÉACTIONS DE TRANSFERT D'ACYLE
  申请人：K H S PHARMA HOLDING GMBH

  公开号：WO2014140318A1

  公开（公告）日：2014-09-18

  The present invention relates to a novel process for the preparation of esters like Aclidinium, Atropin, Glycopyrroniunn, Tiotropium, Trospium and their respective precursors and derivatives, based on direct acyl transfer reactions.

  本发明涉及一种新颖的制备类似Aclidinium、Atropin、Glycopyrroniunn、Tiotropium、Trospium及其各自的前体和衍生物的酯类的过程，基于直接酰基转移反应。